Compare Repligen Corporation Common Stock (RGEN) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Shell PLC — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Shell PLC trades at $104.77 (market cap $290.47B). The key difference: Shell PLC is far larger — about 26.1× Repligen Corporation Common Stock's market cap, and Shell PLC pays a 3.03% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Shell PLC for 91 Days on average.
| RGEN | SHEL | |
|---|---|---|
Market Cap | $11.14B | $290.47B |
Volume | 1,259,263 | 4,901,394 |
Sector | Health | Energy |
52-Week High | $194.57 | $103.58 |
52-Week Low | $102.87 | $70.31 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $11.02B | $332.17B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Shell (SHEL) trades at $103.58, up 1.96% today, near its consensus price target of $103.24. The stock shows bullish momentum with strong earnings beats in Q1 and Q2 2026, though Q4 2025 missed estimates. Recent news highlights expansion in LNG Canada Phase 2, doubling export capacity. Valuation metrics appear reasonable with a P/E of 11.39 and EV/EBITDA of 4.89. Operating cash flow remains robust at $42.86 billion for 2025, supporting dividend payments and strategic investments.
Outlook is positive with analyst consensus favoring Buy ratings (61.54%) and a high price target of $122.40. Key opportunities include LNG growth and portfolio optimization, while risks involve energy price volatility and execution of large-scale projects. The stock's current technical overbought condition may prompt near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
